NYSE:MRKPharmaceuticals
Merck Cardiovascular Readouts Point To New Growth Drivers Beyond Oncology
Merck (NYSE:MRK) reported positive Phase 3 results for its oral PCSK9 inhibitor, enlicitide decanoate, showing marked LDL C reduction and a favorable safety profile.
The company also released Phase 2 WINREVAIR data in combined post and precapillary pulmonary hypertension with heart failure, supporting further clinical development.
These readouts highlight potential franchise expansion for Merck in cardiovascular and cardiopulmonary diseases, extending beyond its existing oncology focus.
For...

